Brief: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
14/01/2025 14:06
Jan 14 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS SUBMITS MARKETING AUTHORIZATION
APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR TROFINETIDE FOR
THE TREATMENT OF RETT SYNDROME
Source text: ID:nBw6H1jsra
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP